Welcome to our dedicated page for Plexus SEC filings (Ticker: PLXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plexus Corp (NASDAQ: PLXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Plexus files periodic and current reports as a Wisconsin corporation with Commission File Number 001-14423.
Among the key documents available are current reports on Form 8-K, which Plexus uses to furnish press releases announcing quarterly and annual financial results. These filings typically include information on revenue, operating margin, earnings per share, non-GAAP performance measures, return on invested capital, free cash flow and other financial metrics, as well as commentary on business conditions and program wins.
Through this page, users can track how Plexus reports its results for fiscal quarters and years, including references to its geographic segments in the Americas, Asia-Pacific and Europe, Middle East and Africa regions, and its focus on Aerospace/Defense, Healthcare/Life Sciences and Industrial market sectors. Filings also confirm corporate details such as state of incorporation and principal corporate location.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of each report. Real-time updates from the SEC’s EDGAR system, along with structured access to forms such as 8-K and other periodic reports, make it easier to review Plexus’ regulatory history and monitor ongoing disclosures related to PLXS.
Plexus Corp executive Angelo Michael Ninivaggi Jr., Exec VP, CAO, General Counsel and Secretary, reported a sale of Plexus common stock. On February 5, 2026, he sold 4,303 shares of common stock at a price of $203.06 per share. After this transaction, he directly beneficially owned 20,099 shares of Plexus common stock.
Plexus Corp. executive Patrick J. Jermain, Exec. VP & CFO, reported a sale of common stock. On February 4, 2026, he sold 3,587 shares of Plexus Corp. common stock at $204.09 per share.
After this transaction, he directly owned 16,882 shares of Plexus common stock. In addition, 3,719 shares were held indirectly in the Plexus Corp. 401(k) Retirement Plan, based on the latest report from the plan’s trustee.
A shareholder of PLXS has filed a notice of proposed sale under Rule 144 for 3,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,500.00, on or about 02/06/2026 on the NASDAQ exchange.
The securities were previously acquired from the issuer as performance shares, including 1,623 shares on 11/13/2024 and 1,377 shares on 02/11/2025. The notice states that the filer is not aware of undisclosed material adverse information about the issuer’s operations.
Plexus Corp. reported fiscal Q1 2026 net sales of $1.07 billion, up about 10% from $976.1 million a year earlier, driven mainly by stronger demand in the AMER region and the Healthcare/Life Sciences sector.
Net income rose to $41.2 million from $37.3 million, with diluted EPS increasing to $1.51 from $1.34. Gross margin slipped to 9.9% from 10.3% as higher fixed costs offset some of the sales growth, while operating margin improved to 5.1% from 4.8% helped by lower restructuring charges.
Free cash flow was negative $50.6 million as the company invested in inventory to support program ramps and raised capital spending. Plexus ended the quarter with $249.4 million in cash and cash equivalents and $158.0 million in debt, finance lease and other financing obligations, and repurchased 152,987 shares for $22.4 million under its 2026 buyback program.
Plexus Corp. director Jennifer Wuamett reported the vesting of restricted stock units into common shares. On February 3, 2026, 1,370 restricted stock units granted under the Plexus Corp. 2024 Omnibus Incentive Plan vested and settled into 1,370 shares of common stock. Following this transaction, she directly owns 3,349 shares of Plexus common stock.
Plexus Corp director Michael V. Schrock reported the vesting of equity awards that delivered 1,370 shares of common stock. The shares came from Restricted Stock Units granted under the Plexus Corp. 2024 Omnibus Incentive Plan, which vested and settled on February 3, 2026.
Following this transaction, Schrock directly held 44,329 shares of Plexus common stock. The RSUs were exercised at an effective price of $0.00 per unit, consistent with stock-based compensation rather than an open-market purchase.
Plexus Corp director Paul A. Rooke reported the vesting of restricted stock units that converted into common shares. On February 3, 2026, 1,370 Restricted Stock Units granted under the Plexus Corp 2024 Omnibus Incentive Plan vested and settled into 1,370 shares of common stock at a stated price of $0 per share. Following this equity award settlement, Rooke directly holds 15,991 shares of Plexus common stock.
Plexus Corp. director Karen Marie Rapp reported the vesting of equity awards and the corresponding issuance of common shares. On February 3, 2026, 1,370 Restricted Stock Units granted under the Plexus Corp. 2024 Omnibus Incentive Plan vested and settled into 1,370 shares of Plexus common stock at an exercise price of $0.00 per share. Following this conversion, she directly beneficially owned 9,035 shares of Plexus common stock.
Plexus Corp director J. Joel Quadracci reported the vesting of equity awards under the company’s 2024 Omnibus Incentive Plan. On February 3, 2026, 1,370 Restricted Stock Units converted into an equal number of Plexus common shares at no cost. Following this settlement, Quadracci directly holds 7,478 shares of common stock, reflecting equity compensation rather than an open-market purchase.
Plexus Corp. director Randy J. Martinez reported the vesting of equity compensation under the company’s 2024 Omnibus Incentive Plan. On February 3, 2026, 1,370 restricted stock units converted into 1,370 shares of Plexus Corp. common stock at an exercise price of $0.00 per share.
After this settlement, Martinez directly owned 6,201 shares of Plexus Corp. common stock. The restricted stock units represented a contingent right to receive one share of common stock per unit and vested and settled in full on February 3, 2026.
FAQ
What is the current stock price of Plexus (PLXS)?
What is the market cap of Plexus (PLXS)?
